Compare GSK plc (GSK) vs Mercadolibre Inc (MELI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Mercadolibre Inc — how do they compare? GSK plc trades at $52.66 (market cap $101.34B), while Mercadolibre Inc trades at $1,851.42 (market cap $93.44B). The key difference: GSK plc and Mercadolibre Inc are close in size by market cap, and GSK plc pays a 3.49% dividend while Mercadolibre Inc pays none. Which is the better fit depends on your goals.
| GSK | MELI | |
|---|---|---|
Market Cap | $101.34B | $93.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $61.18 | $2.51K |
52-Week Low | $36.20 | $1.55K |
Enterprise Value | $121.95B | $100.33B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
MercadoLibre (MELI) trades at $1,873.88, showing modest daily gains of 0.35% amid a generally bullish technical outlook. The stock exhibits strong fundamental growth with 2025 revenue reaching $28.89B and net income of $2.00B, though recent quarterly EPS results have missed analyst expectations. The company is strategically investing heavily in logistics, fulfillment, and fintech expansion, which is pressuring near-term margins but positioning for long-term market dominance in Latin America.
The investment outlook balances robust top-line growth and a dominant competitive position against margin compression from strategic investments and recent earnings misses. Wall Street sentiment remains overwhelmingly positive with a $2,230 consensus price target, but investors face risks from execution on growth investments, competitive pressures, and ongoing legal investigations highlighted in recent news.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →
